vTv Therapeutics (VTVT) Common Equity (2016 - 2025)
Historic Common Equity for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $70.5 million.
- vTv Therapeutics' Common Equity rose 29380.9% to $70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.5 million, marking a year-over-year increase of 29380.9%. This contributed to the annual value of $14.3 million for FY2024, which is 15794.57% up from last year.
- According to the latest figures from Q3 2025, vTv Therapeutics' Common Equity is $70.5 million, which was up 29380.9% from $2.8 million recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' Common Equity registered a high of $70.5 million during Q3 2025, and its lowest value of -$56.3 million during Q1 2021.
- Moreover, its 5-year median value for Common Equity was -$9.7 million (2021), whereas its average is -$5.9 million.
- Per our database at Business Quant, vTv Therapeutics' Common Equity plummeted by 19654.0% in 2023 and then skyrocketed by 29380.9% in 2025.
- Quarter analysis of 5 years shows vTv Therapeutics' Common Equity stood at -$9.7 million in 2021, then decreased by 10.27% to -$10.7 million in 2022, then crashed by 129.8% to -$24.7 million in 2023, then surged by 157.95% to $14.3 million in 2024, then surged by 393.27% to $70.5 million in 2025.
- Its Common Equity stands at $70.5 million for Q3 2025, versus $2.8 million for Q2 2025 and $8.9 million for Q1 2025.